Belgian bioventure argenx N.V. has made a rapid and smooth entry into the sometimes challenging Japanese market with its generalized myasthenia gravis (gMG) drug Vyvgart (efgartigimod alfa).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?